Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection

Yong-rui YANG; Hai-wen LI; Zhi-rong ZHAO; Lu WANG; Ting JIA; Zhi-jian DONG; Xiao-fei LI; Ni-hong LU

doi:10.12259/j.issn.2095-610X.S20210722

Volume 42 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(7): 130-136

Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection[J]. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722

Citation:

Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection[J]. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722

Citation:

Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection[J]. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722

PDF( 664 KB)

Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection

doi: 10.12259/j.issn.2095-610X.S20210722

Dept. of Hepatology，The 3rd People’s Hospital of Kunming/Yunnan Provincial Infectious Disease Clinical Medicine Center，Kunming Yunnan 650041，China

Received Date: 2021-04-25
Available Online: 2021-07-19
Publish Date: 2021-07-21

Abstract

Abstract

Objective To observe the efficacy and safety of SofosbuvirVelpatasvir in the treatment to chronic hepatitis C combining with HCV/HIV. Methods 419 patients with chronic hepatitis C and 56 patients with HCV/HIV that were admitted to Kunming Third People’ s Hospital were selected for this study. All kind of indicators such as virological response （SVR）, biochemical responses, and liver Fibrosis have been continuously monitored during the treatment of 4 weeks, 12 weeks, as well as additional 12^th week follow-up after treatment termination. Results After 12-week treatment the genotype 1 patient solely with HCV has SVR12 of 97.56%; the genotype 2 patient has SVR12 of 98.97%; the genotype 3 patients has SVR12 of 97.54% while the genotype 6 has SVR12 of 97.85%, P = 0.870. In contrast, the patients with HCV/HIV co-infection were treated with SofosbuvirVelpatasvir besides their HIV treatment. After 12 weeks of the treatment, the genotype 1 patient showed SVR12 of 85.71%; the genotype 3 showed SVR12 of 92.11%; the genotype 6 shows SVR12 of 90.91%, P = 0.862. Also, after antiretroviral therapy both patients show the significant improvement in the biochemical indictors, AST, ALT and ALB as well as the renal function. The hepatic fibrosis index from both decreases significantly after the treatment. For the adverse reactions, diarrhea, nausea, vomiting and fatigue were found in GT3 genotype patients, while fatigue and headache were the most common in other genotypes patients and HCV/HIV co-infected patients. Conclusion Sofosbuvir and Vipatavir have high efficacy and good safety in the treatment to the patient with chronic hepatitis C and HCV/HIV co-infection.
- C hronic hepatitis C,
- HIV,
- Antiviral therapy

FullText(HTML)

References(15)

References

[1]	中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志,2019,35(12):2670-2686.
[2]	刘炜炜,胡跃华,于石成,等. 中国大陆地区2008—2013年丙肝发病时空聚集性及社会经济影响因素[J]. 中国公共卫生,2016,04(32):482-487.
[3]	中华医学会感染病学分会艾滋病学组. 中国艾滋病诊疗指南(2018版)[J]. 中华传染病杂志,2018,36(12):705-724.
[4]	揣征然,张云辉,赵雅琳,等. 全球及中国AIDS最新疫情概况[J]. 传染病信息,2020,33(6):501-503. doi: 10.3969/j.issn.1007-8134.2020.06.002
[5]	孔毅,许琳,康文玉,等. 云南省1959-2014年病毒性肝炎流行特征分析[J]. 中国卫生统计,2016,33(4):657-659.
[6]	罗楠,毛志鹏. 昆明市2013—2017年丙型病毒性肝炎流行特征及趋势分析[J]. 中国卫生产业,2020,17(5):188-189.
[7]	肖民扬,付丽茹,罗红兵,等. Spectrum/EPP模型在云南省艾滋病流行趋势评估的应用[J]. 中国艾滋病性病,2020,26(11):1221-1225.
[8]	刘俊,田波,李重熙,等. 昆明地区HIV/HCV共感染者不同CD4水平肝功能对比研究[J]. 昆明医学院学报,2012,33(2):138-139.
[9]	Struble Kimberly,ChanTack Kirk,Qi Karen,et al. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virusgenotype[J]. U S Food and Drug Administration’s evaluation,2018,67(2):482-491.
[10]	付婧婕,张苑玲,蔡秋红,等. 索磷布韦维帕他韦片治疗慢性丙肝的临床研究[J]. 重庆医科大学学报,2020,3(10):1464-1468.
[11]	李荣健,高榆. HIV和HCV合并感染现状及丙型肝炎治疗进展[J]. 实用预防医学,2020,27(11):1406-1409.
[12]	段振华,奚静,代珍,等. 成都市HCV合并感染对HIV/AIDS抗病毒治疗效果的影响[J]. 中华疾病控制杂志,2020,24(12):1403-1406.
[13]	张怀东. DAAs治疗慢性丙型肝炎的疗效及安全性分析[D]. 南宁: 广西医科大学硕士论文, 2019.
[14]	刘立,李俊义,刘春云,等. 索非布韦联合达拉他韦治疗基因3型慢性丙型肝炎的疗效和安全性研究[J]. 中国病毒病杂志,2018,8(5):384-388.
[15]	黄杰庭,许茹,廖峭,等. HCV 3b亚型全长序列测定及基线耐药相关置换的分析[J]. 临床肝胆病杂志,2020,36(1):94-97.

Relative Articles(20)

Relative Articles

[1]	Bo TIAN, Jun LIU, Chongxi LI, Wei ZHANG, Meiqin FANG, Haiyun CHEN, Jingping BAI, Xin ZHOU, Lei CHENG, Yongmei JIN. Effect Observation and Influencing Factors Analysis of Rapid Initiation of Antiretroviral Therapy. Journal of Kunming Medical University, 2024, 45(9): 163-167. doi: 10.12259/j.issn.2095-610X.S20240925
[2]	Yihan LIU, Jun LIU, Yongmei JIN, Bo TIAN, Jinsong BAI. Risk Assessment and Analysis of Risk Factors for Cardiovascular Disease in HIV Antiviral Therapy Patients. Journal of Kunming Medical University, 2024, 45(10): 140-146. doi: 10.12259/j.issn.2095-610X.S20241022
[3]	Qian AI, Zhirong ZHAO, Yue WU, Haiwen LI, Shenghao LI, Yongrui YANG. Analysis of Antiviral Efficacy and Safety in Patients with Chronic Hepatitis B in Indeterminate Phase. Journal of Kunming Medical University, 2024, 46(): 1-9.
[4]	Ti WU, Kang HUANG, Zhirong ZHAO, Haiwen LI, Xiaofei LI, Yongrui YANG. The Efficacy and Safety of Different Antiviral Treatment Regimens in Patients with ALT Elevation and Low Viral Load in the Indeterminate Phase of Chronic Hepatitis B. Journal of Kunming Medical University, 2023, 44(1): 97-103. doi: 10.12259/j.issn.2095-610X.S20230117
[5]	Bo TIAN, Chongxi LI, Yongmei JIN, Wei GUAN, Haiyun CHEN, Jun LIU. Use and Replacement of Treatment Regimens for AIDS Patients on Antiretroviral Therapy. Journal of Kunming Medical University, 2023, 44(5): 162-167. doi: 10.12259/j.issn.2095-610X.S20230508
[6]	Xiaomei JIN, Jieyan HE, Jichang SHI, Hui XING, Hong WANG, Ju ZHANG, Lijuan DONG, Lihua HUANG, Min CHEN, Zhijuan CHEN, Huichao CHEN. Virus Genotypes and Drug Resistance among HIV/AIDS Patients before Antiretroviral Therapy in Dali Bai Autonomous Prefecture in 2018. Journal of Kunming Medical University, 2023, 44(11): 152-157. doi: 10.12259/j.issn.2095-610X.S20231123
[7]	Tingting YU, Dongling LI, Hongying WANG, Lihua LI, Dong PU, Kunli WU. Investigations on the Infection, Immunity and Drug Resistance of Newly-treated Cases of HIV in Kunming. Journal of Kunming Medical University, 2022, 43(1): 138-143. doi: 10.12259/j.issn.2095-610X.S20220133
[8]	Rui CAO, Chang XU, Xiaomei JIN, Jie DAI, Huichao CHEN, Lijuan DONG, Min YANG, Li YANG, Min CHEN. Analysis of Recent Infections Among HIV-1 Infected MSM in Kunming City from 2018 to 2020. Journal of Kunming Medical University, 2022, 43(8): 150-155. doi: 10.12259/j.issn.2095-610X.S20220825
[9]	Chongxi LI, Guangfeng YIN, Yushu ZHANG, Shanqun GU, Wei ZHANG, Jun LIU, Bo TIAN. Prevalence of Kidney Disease among Pre-ART Patients with HIV Infection in Kunming and The Influencing Factors. Journal of Kunming Medical University, 2022, 43(2): 154-159. doi: 10.12259/j.issn.2095-610X.S20220208
[10]	Ting-ting YU, Xiao-fei LI, Hong-ying WANG, Run-wu ZHANG, Cai-mei DING, Li-hua LI, Jing BAI, Dong-ling LI, Dong PU. Application of Viral Load Testing in Diagnosing 102 Cases of Indeterminate HIV Antibody. Journal of Kunming Medical University, 2020, 41(11): 130-133. doi: 10.12259/j.issn.2095-610X.S20201126
[11]	Li Zhong Xi , Liu Jun , Bai Jing Song , Tian Bo , Yu Min , Gu Shan Qun . . Journal of Kunming Medical University, 2019, 40(01): 92-95.
[12]	Li Zhong Xi , Liu Jun , Guan Wei , He Rong , Zhang Wei , Bai Jing Song . . Journal of Kunming Medical University, 2019, 40(08): 102-106.
[13]	Yang Yong Rui , Li Fei , Yang Yin , Wen Pin Yuan , Feng Yu , Shen Jiu Cheng , Zhang Jian Qing , Shen Ling . . Journal of Kunming Medical University, 2018, 39(10): 126-129.
[14]	Shi Xin Huan , Tang Rui Zhu , Liu Zi Jie , Lu Yan Zhou , Li Huan . The Changes of Hepatitis C Virus Gene Subtypes and RNA Loads in the Development of Chronic Hepatitis C Patients in Yunnan. Journal of Kunming Medical University, 2018, 39(06): 57-61.
[15]	Liu Li , Wang Ya Ling , Bai Jing Song , Wang Li Xi , Wang Wei Bo , Chen Xiao Juan . Application of Cluster Nursing in Mechanical Ventilation Treatment of HIV Infection Complicated with Pulmonary Tuberculosis. Journal of Kunming Medical University, 2017, 38(07): 147-150.
[16]	Zhou Gui , Shu Hai Yan , Luo Jiang Cun , Su Chao Min , Song Lie Xi , Liu Jia , Yang Jiao , Wang Hui Ling . Monitoring Results of HIV Infection in a Hospital in Chengdu. Journal of Kunming Medical University, 2016, 37(12): 122-126.
[17]	Lan Qing . . Journal of Kunming Medical University,
[18]	Li Xian Li . . Journal of Kunming Medical University,
[19]	Wang Juan Li . . Journal of Kunming Medical University,
[20]	Sun Tao . . Journal of Kunming Medical University,